- Conditions
- Multiple Sclerosis
- Interventions
- NLY01, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
- Interventions
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Drug · Diagnostic Test
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Dietary Change, Obesity & Overweight, Food Acceptance
- Interventions
- Pistachios, Dual-energy X-ray absorptiometry (DEXA) scans
- Dietary Supplement · Procedure
- Lead sponsor
- Ian J. Neeland, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Clevland, Ohio
- Conditions
- COPD, Obesity & Overweight, Sarcopenia
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Psoriatic Arthritis (PsA)
- Interventions
- GLP-1 agonists, Nutrition Counseling
- Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Obesity, Menopause
- Interventions
- semaglutide or tirzepatide, Lifestyle modification intervention
- Drug · Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 46 Years to 60 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Type 2 Diabetes (T2DM)
- Interventions
- SGLT-2 inhibitor, GLP1-RA
- Drug
- Lead sponsor
- MaryAnn Banerji
- Other
- Eligibility
- 24 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
- Interventions
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Eden Prairie, Minnesota
- Conditions
- Obesity
- Interventions
- OverStitch™ or OverStitch NXT™, Lifestyle Modification
- Device · Behavioral
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Obesity/Therapy
- Interventions
- Semaglutide 1.7mg subcutaneous, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes, Gastric Content Aspiration, Glucagon-like Peptide 1, GLP-1
- Interventions
- Gastric Ultrasound
- Diagnostic Test
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
- Interventions
- Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Columbus, Ohio • Upper Arlington, Ohio
- Conditions
- Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia, Respiratory Aspiration of Gastric Contents
- Interventions
- Ultrasound of gastric contents
- Diagnostic Test
- Lead sponsor
- Wael Saasouh, MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Obesity, Overweight, Taste Perception, Olfaction, Eating Behavior, Appetite
- Interventions
- Not listed
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Interventions
- Semaglutide Injectable Product, Placebo
- Drug
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Charleston, South Carolina
- Conditions
- Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Semaglutide (Rybelsus®), Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Diabetic Kidney Disease (DKD)
- Interventions
- Kidney-Protective Therapies Used in Routine Care
- Drug
- Lead sponsor
- Rubix LS
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lawrence, Massachusetts
- Conditions
- Severe Obesity, Obesity, BMI Greater Than 30
- Interventions
- Tirzepatide, Standard of Care post-gastric bypass
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Obesity, Diabetes Type 2
- Interventions
- Semaglutide Pen Injector [Ozempic]
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Interventions
- SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 241,981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania